FierceBiotech ✓

@FierceBiotech · Washington, DC · joined 21 Dec 2008

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

102 606Followers

623Following

29 716Posts total

18.8KViews on collected posts

Against accounts of the same size

7 posts from the last 90 days, next to the 100K–1M follower range. below its peers on both reach and engagement.

Median views796this account5 994median for 100K–1M

Reach, %0.78%this account2.51%median for 100K–1M

Engagement, %0.41%this account1.40%median for 100K–1M

Metric	This account	Median for 100K–1M	Ratio
Median views per post	796	5 994	0.13×
Reach (views ÷ followers)	0.78%	2.51%	0.31×
Engagement rate	0.41%	1.40%	0.29×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

4.1K28 Aug

2429 Aug

3.6K1 Sep

9.5K2 Sep

7964 Sep

767

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.71%28 Aug

1.45%

0.00%29 Aug

0.20%1 Sep

0.41%2 Sep

0.25%4 Sep

0.65%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 1.40%.

What the audience does

Likes70.2%73 in total

Reposts4.8%5 in total

Replies2.9%3 in total

Quotes1.9%2 in total

Bookmarks20.2%21 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

A study published in Science showed that giving psilocybin before chemotherapy prevented the development of pain hypersensitivity caused by neurotoxic chemotherapies, with protection maintained up to 8 months in mice. https://t.co/ubMtNeqZ0q 767 views · 5 likes · 0 reposts · 0 replies 04 Sep 2026 Noubar Afeyan has built a career around an unusual premise: Instead of waiting for the next biotech breakthrough, create the conditions for one. The Flagship Pioneering founder is a 2026 Fierce 50 Leadership honoree. 🔗 https://t.co/vVRn0W1emH @FlagshipPioneer #Fierce50 https://t 796 views · 2 likes · 0 reposts · 0 replies 04 Sep 2026 By targeting large unmet markets in hair loss and endometriosis with a direct-to-consumer approach, Absci is on a mission to become a household name. https://t.co/tzOcIXS0ia 9.5K views · 35 likes · 2 reposts · 0 replies 02 Sep 2026 The 2026 Fierce 50 is live. Among this year’s honorees are scientists, biotech leaders and organizations pushing into new areas of drug development, diagnostics and patient care. https://t.co/jGb5ppJjBV https://t.co/8C55jDZ3J3 3.6K views · 5 likes · 1 reposts · 1 replies 01 Sep 2026 @FierceBiotech New modalities only reach patients if there are people who can take them from bench to GMP production. On ATMP growth in the Netherlands and the talent it demands: https://t.co/gnLFZOKcZo 24 views · 0 likes · 0 reposts · 0 replies 29 Aug 2026 @FierceBiotech rare disease tRNA plays are a small market until one hits and becomes the platform everyone retroactively calls obvious 69 views · 1 likes · 0 reposts · 0 replies 28 Aug 2026 With mRNA back in the spotlight, tRNA shows potential to treat genetic disease https://t.co/TA9y64vG1l 4.1K views · 25 likes · 2 reposts · 2 replies 28 Aug 2026